Drugs Target Clinical Trial Number Phase   Diseases treated Etanercept® TNF-α NCT00203359 I Alzheimer’s Disease Pegsunercept® sTNFR1 NCT00111423 II/III RA Adlimumab® TNF-α NCT00837434 IV RA Etanercept® TNF-α NCT00477191 I Metabolic Syndrome and Psoriasis TNF Kinoid TNF-α NCT01040715 II Relapsed RA patients treated with MAb TACE/ADAM17 inhibitor TACE/ ADAM-17 N/A N/A RA[113], Crohn’s disease [114], pulmonary inflammation [115], psoriasis [200]

Table 2: Experimental drugs targeting TNF-α and its related pathways in various diseases. Abbreviations: TNF or TNF-α, tumor necrosis factor-α; sTNFR1, soluble tumor necrosis factor-α receptor 1, TACE/ADAM-17, TNF-α -converting enzyme/a disintegrin and metalloproteinase domain 17; RA, rheumatoid arthritis; N/A, not applicable.